Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer54

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer7

Views

Views
October 20251
November 20252
December 20252
January 20261
February 20260
March 20261
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United Kingdom3
Argentina2
Colombia1
United States1
 

Top cities views

Views
City of Westminster1
Córdoba1
Florida1
Medellín1